Table 3.
Univariate and multivariate analyses of prognostic factors
| Variable |
Overall survival |
Recurrence-free survival |
||||
|---|---|---|---|---|---|---|
|
Univariate |
Multivariate |
Univariate |
Multivariate |
|||
| p | HR (95% CI) | p | p | HR (95% CI) | p | |
| Age, year (≤50 vs >50) |
0.719 |
|
N.A. |
0.881 |
|
N.A. |
| Gender (female vs male) |
0.013 |
|
N.A. |
0.003 |
|
N.A |
| ALT, U/L (≤40 vs >40) |
0.264 |
|
N.A. |
0.800 |
|
N.A. |
| γ-GT, U/L (≤55 vs >55) |
0.030 |
|
N.A. |
0.581 |
|
N.A. |
| ALP, U/L (≤121 vs >121) |
0.007 |
|
N.A |
0.077 |
|
N.A |
| Serum albumin, g/L (<35 vs ≥35) |
0.632 |
|
N.A |
0.712 |
|
N.A |
| AFP, ng/ml (≤20 vs >20) |
0.095 |
|
N.A. |
0.169 |
|
N.A. |
| HBsAg (negative vs positive) |
0.207 |
|
N.A. |
0.449 |
|
N.A. |
| Tumor size, cm (≤5 vs >5) |
6.0E-05 |
2.950 (1.694-5.137) |
1.3E-04 |
0.003 |
1.804 (1.057-3.080) |
0.031 |
| Tumor number (single vs multiple) |
0.006 |
|
N.A. |
3.3E-05 |
|
N.A. |
| Tumor capsule (yes vs none) |
0.016 |
|
N.A. |
0.015 |
|
N.A. |
| Microscopical intrahepatic metastasis (no vs yes) |
0.165 |
|
N.A. |
0.021 |
|
N.A. |
| Microscopic vascular invasion (no vs yes) |
0.354 |
|
N.A. |
0.017 |
|
N.A. |
| Portal vein invasion (no vs yes) |
0.004 |
|
N.A. |
0.348 |
|
N.A. |
| BCLC stage (A vs B/C) |
3.3E-08 |
2.738 (1.602-4.679) |
2.3E-04 |
2.2E-07 |
|
N.A. |
| TNM stage (I vs II /III) |
1.8E-07 |
|
N.A. |
3.4E-08 |
3.597 (2.046-6.324) |
8.8E-06 |
| Necroinflammatory grade (<9 vs ≥9) |
0.001 |
|
N.A. |
0.003 |
1.837 (1.087-3.105) |
0.023 |
| Fibrotic stage (≤4 vs >4) |
0.014 |
|
N.A. |
0.103 |
|
N.A. |
| DR (<2 vs ≥2) |
2.6E-05 |
4.294 (2.255-8.177) |
9.3E-06 |
4.8E-04 |
2.380 (1.250-4.534) |
0.008 |
| Liver ischemic time, min (≤25 vs >25) |
0.760 |
|
N.A. |
0.683 |
|
N.A. |
| Blood loss, ml (<800 vs ≥800) |
0.007 |
|
N.A. |
0.063 |
|
N.A. |
| Blood transfusion (yes vs no) | 0.089 | N.A. | 0.071 | N.A. | ||
The median was used as cut-off of necroinflammatory grade, fibrotic stage and DR respectively. Variables with p <0.05 in univariate analysis were adopted for multivariate analysis. Tumor size and DR were included, other covariates including tumor number, tumor capsule and portal vein invasion were then excluded.